Shanghai InnoStar Bio-tech Co., Ltd. (SHA:688710)
China · Delayed Price · Currency is CNY 90.10
+6.74 (8.09%)
At close: Oct 28, 2026
SHA:688710 Revenue
Shanghai InnoStar Bio-tech had revenue of 321.40M CNY in the quarter ending September 30, 2026, with 64.43% growth. This brings the company's total for the last twelve months to 1.03B, up 23.75% year-over-year. In the year 2025, Shanghai InnoStar Bio-tech had annual revenue of 811.33M, down -28.94%. That makes Shanghai InnoStar Bio-tech the 19,395th largest company in the world by revenue and 3,549th in China.
Revenue (ttm)
1.03B
Revenue Growth
+23.75%
P/S Ratio
12.37
Revenue / Employee
854.43K
Employees
1,202
Market Cap
12.70B
Revenue by Geography
- China 761.52M 93.9%
- Overseas 49.81M 6.1%
Fiscal year ended Dec 31, 2025 See the full SHA:688710 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 811.33M | -330.34M | -28.94% |
| Dec 31, 2024 | 1.14B | 103.24M | 9.94% |
| Dec 31, 2023 | 1.04B | 175.36M | 20.32% |
| Dec 31, 2022 | 863.07M | 281.30M | 48.35% |
| Dec 31, 2021 | 581.77M | 248.00M | 74.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 54.82B |
| Zhejiang Int'l Group | 34.69B |
| Yifan Pharmaceutical | 4.93B |
| Zhejiang Jolly Pharmaceutical Co.,LTD | 3.21B |
| GuangYuYuan Chinese Herbal Medicine | 1.41B |
| Zhejiang Wolwo Bio-Pharmaceutical | 1.12B |
| Chongqing Lummy Pharmaceutical | 720.01M |
| Hangzhou Bio-Sincerity Pharma-Tech | 650.08M |